[1]
Khalaf, D.J., Avilés, C.M., Azad, A.A., Sunderland, K., Todenhöfer, T., Eigl, B.J., Finch, D., Le, L., Atwell, A., Keith, B., Kollmannsberger, C. and Chi, K.N. 2017. A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Canadian Urological Association Journal. 12, 2 (Dec. 2017), E47–52. DOI:https://doi.org/10.5489/cuaj.4600.